One Penn Plaza
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.
128 articles with Ophthotech
Ophthotech Corporation Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
Ophthotech Treats First Patient in a Phase I Trial of Monoclonal Antibody, Volociximab, for Age-Related Macular Degeneration
Ophthotech Enrolls First Patient in a Phase I Complement (Anti-C5) Inhibitor Trial for Macular Degeneration
Archemix Corporation Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech
Biogen Idec, Inc. (Massachusetts) and PDL BioPharma, Inc. License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech